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Background: The modified Glasgow Prognostic Score (mGPS) has been reported to be an important prognostic
indicator in a number of tumor types, including colorectal cancer (CRC). The features of the inflammatory state
thought to accompany elevated C-reactive protein (CRP), a key feature of mGPS, were characterized in patients with
colorectal liver metastases. Additional inflammatory mediators that contribute to prognosis were explored.
Methods: In sera from 69 patients with colorectal liver metastases, a panel of 42 inflammatory mediators were
quantified as a function of CRP levels, and as a function of disease-free survival. Multivariate statistical methods were
used to determine association of each mediator with elevated CRP and truncated disease-free survival.
Results: Elevated CRP was confirmed to be a strong predictor of survival (HR 4.00, p = 0.001) and recurrence
(HR 3.30, p = 0.002). The inflammatory state associated with elevated CRP was comprised of raised IL-1β, IL-6, IL-12
and IL-15. In addition, elevated IL-8 and PDGF-AB/BB and decreased eotaxin and IP-10 were associated with worse
disease-free and overall survival.
Conclusions: Elevated CRP is associated with a proinflammatory state. The inflammatory state is an important
prognostic indicator in CRC liver metastases. The individual contributions of tumor biology and the host to this
inflammatory response will require further investigation.
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Colorectal cancer (CRC) is the second leading cause of
cancer death in the western world. The liver is the most
common site of metastases, affecting approximately
25–35% [1]. Liver metastases are the most common
cause of death in CRC patients [1]. Although there are
a number of therapies for treating metastatic CRC iso-
lated to the liver, including ablative therapies and sys-
temic chemotherapy, resection remains the mainstay
of treatment for potential cure. With resection, sur-
vivals have steadily improved with advances in surgical
technique and systemic therapy. In more recent series,
median survival is now greater than 50 months and 5-year
survival exceeds 50% [2-4].
With the expansion of therapeutic options, it is becom-
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reproduction in any medium, provided the orstrategy comprising various sequences of systemic therapy
and surgery. For example, if a subset of individuals is
known to have short disease-free survivals after resection,
systemic therapy may play a more important role, either
instead of resection or as an adjunct to resection. To this
end, clinical risk scores have been developed to stratify
patients by prognosis [5-13]. Clinical risk scores are easily
employed because the data are readily available from
standard preoperative tests employed in clinical practice.
However, they shed little insight on the underlying biology
of the disease, which is integral to the formulation of new
therapeutic strategies.
The modified Glasgow Prognostic Score (mGPS) [14]
is a rudimentary means to derive a picture of the overall
biological state. The mGPS, based on serum C-reactive
protein (CRP) and albumin, was described by McMillan
and coworkers [15]. Several series have demonstrated
that mGPS effectively stratifies patients by prognosis in
CRC [16,17], including CRC liver metastases [18-21].
mGPS also effectively prognosticates in cancers of theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ney [22-28]. mGPS is thought to reflect the inflammatory
state, although the nature of the inflammatory state has not
yet been characterized, and the contributions of tumor and
host to this inflammatory state have not been delineated.
Understanding the underlying biology of mGPS may
leverage its use as a tool to make treatment decisions.
That is, with a better comprehension of the inflamma-
tory pathways associated with poor clinical outcomes, it
may be possible to redirect the inflammatory response
to a more favorable course. The aim of the present study
was to characterize the inflammatory state associated
with elevated CRP, the main parameter influencing mGPS.
A panel of 42 inflammatory mediators, including cytokines
and chemokines, were evaluated as a function of CRP.
In addition, other important prognostic inflammatory
mediators were identified, which may further refine any
inflammation-based prognostic scoring system.
Methods
This study was approved by the Conjoint Health
Research Ethics Board at the University of Calgary
(Ethics ID E21805). Clinically annotated serum samples
were collected prospectively from consented patients who
underwent surgery for resection of liver metastases. All
patients were treated at the Foothills Medical Centre, a
tertiary referral centre, between 2006 and 2011. Patients
with extrahepatic disease, or any acute inflammation or
sepsis were specifically excluded. Surgical pathology was
reviewed for all patients, and confirmed all had colorectal
adenocarcinoma. Samples were collected in a plastic gold
top Vacutainer tube (BD Biosciences), which contained a
clot activator and a gel for serum separation. Samples
were processed within 6 hours of collection, then frozen
at −20°C until the time of analysis. All samples were
collected from patients who had fasted, prior to surgery.
The inflammatory state was characterized in sera using
a multiplexed protein bead assay (Luminex, Austin, TX),
which measured 42 different inflammatory mediators.
Two cytokines (IL-3 and IL-9) were removed from the
subsequent analysis due to their high number of zero
values (69/70 and 68/70, respectively).
Data analysis
Patients were allocated to one of two groups, based on a
CRP cutpoint level of 10 mg/L, as reported by others
[14-16,18,19]. Descriptive statistics were utilized to
characterize the clinical parameters of groups: unpaired
t-tests with unequal variances assumed (Welch’s t-test)
were used to compare means, and Fisher’s exact tests
were used to compare categorical variables. Quarter-root
transformations were employed to improve data symmetry
while preserving zero scores assigned to cytokine values
below the assay detection limit. All tests of significancewere 2-sided and a p-value less than 0.05 was considered
a priori to represent statistical significance between groups
of patients in these univariate analyses.
To identify individual cytokines associated with ele-
vated CRP, two-sample t-tests as well as penalized logis-
tic regression methods were applied based on the elastic
net approach [29,30]. Multiple testing adjustment for the
two-sample t-tests was taken into account with the False
Discovery Rate via the Significance Analysis Microarrays
(SAM) program, which also provides an estimated p-value
cutoff for a specified false discovery rate [31].
Kaplan-Meier survival plots and Cox Proportional
Hazards regression models were used to evaluate the asso-
ciation between cytokines and disease-specific survival.
The primary endpoints for that analysis were disease-free
survival and overall survival, calculated from date of sur-
gery. Patients without recurrence were censored at their
date of last follow-up.
Results
Inflammatory mediators associated with elevated CRP
Serum inflammatory mediators were evaluated in 70
patients who were considered for surgery. One patient
who underwent resection had a recent tooth infection
at time of serum sample collection and consequently
was excluded from analysis. CRP was measured in the
69 patients with CRC liver metastases and the inflamma-
tory profile was evaluated to determine the nature of the
inflammatory response associated with elevated CRP.
The median age for the entire cohort was 61 years
(range 29–86), and of those assessed there were 47 males
(68%) and 22 females (32%). The median CEA was 5.0
(range 0.6–682). Liver metastases were synchronous in 36
patients (52%). Of those patients with synchronous liver me-
tastases, all had undergone resection of the primary tumor
prior to liver resection (and prior to blood collection);
no patients were treated with simultaneous colon and
liver resections.
A total of 40 inflammatory mediators were tested for
their association with elevated CRP (Additional file 1:
Table S1). By univariate analysis, there were 4 cytokines
that were strongly associated with an elevated CRP: IL-1β,
IL-6, IL-12, and IL-15 (Table 1). After adjusting for multiple
hypothesis testing using the false discovery rate (FDR),
3 cytokines, IL-1β, IL-12, and IL-15 were found to be
significantly associated with elevated CRP (Table 1).
Prognostic inflammatory profile in resected liver metastases
To understand which inflammatory mediators were of
biological significance, we evaluated mediators associated
with recurrence and overall survival. For this analysis, only
patients that had a resection were evaluated. Of the 69
patients initially assessed, four patients had progres-
sion of disease and did not proceed to surgery, and 13
Table 1 Cytokines significantly associated with elevated CRP
using univariate and multiple hypothesis testing analysis






SAM - Significance analysis of microarrays.
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were excluded from further analysis. The baseline clinical
and pathologic characteristics of patients in the study who
had a liver resection are represented in Table 2. A total of
27 patients (52%) had a normal CRP (<10 mg/L) and 25Table 2 Clinical and pathologic characteristics of resected
patients with normal and elevated CRP levels
CRP < 10 CRP ≥ 10
n % n % P-value
Age (years)
< 65 15 55.6 15 60.0 0.785
≥ 65 12 44.4 10 40.0
Gender
Male 18 66.7 16 64.0 1.000
Female 9 33.3 9 36.0
Neoadjuvant chemo
Yes 13 48.1 15 62.5 0.400
No 14 51.9 9 37.5
Adjuvant chemo
Yes 16 66.7 14 66.7 1.000
No 8 33.3 7 33.3
CEA (ng/mL)
< 20 15 68.2 19 79.2 0.508
≥ 20 7 31.8 5 20.8
Disease-free interval (months)
< 12 21 77.8 14 56.0 0.140
≥ 12 6 22.2 11 44.0
Resection margin
Negative 25 92.6 18 72.0 0.071
Positive 2 7.4 7 28.0
Number of tumors
1 14 53.8 12 54.5 1.000
> 1 12 46.2 10 45.5
Largest tumor size (cm)
< 5 22 84.6 15 68.2 0.301
≥ 5 4 15.4 7 31.8
CRP - C-Reactive Protein.
CEA - Carcinoembryonic Antigen.
Some missing data.patients had an elevated CRP (≥10 mg/L). Liver resection
was performed in 34 males (65%) and 18 females (35%).
The median age was 61 years (range 29–86). Neoadjuvant
chemotherapy was administered in 28 patients (54%),
adjuvant chemotherapy was administered in 30 patients
(58%). Median CEA was 3.2 (range 0.6–134). Liver metasta-
ses were synchronous in 28 patients (54%). In 43 patients
(83%), R0 resections were achieved; the remainder had
positive microscopic margins. Solitary metastases were
resected in 50%; up to 7 lesions were resected in any indi-
vidual. The median tumor size was 3.5 cm (range 0.5–9.0).
There was no significant difference in any of these factors
between the group with a normal CRP and the group with
elevated CRP (Table 2). Specifically, CRP levels did not
vary as a function of chemotherapy, CEA level, or number
and size of metastases.
Median follow-up for patients still alive was 20 months
(range 1–49 months). During follow-up, 15 patients (28%)
died, and 31 patients (58%) developed recurrent disease.
The median overall survival in patients with normal and
elevated CRP was 79 months and 41 months, respectively
(Figure 1A). However, this difference was not statistically
significant by log rank test. The median disease-free survival
in patients with normal CRP was 23 months and, in pa-
tients with elevated CRP, was 13 months (Figure 1B). Again,
this was not statistically significant by log rank test, due to
the small sample size. However, when CRP was analyzed as
a continuous variable (as opposed to a binary variable),
it was found to be a strong predictor of overall survival
(hazard ratio 4.00; Table 3) and disease-free survival
(hazard ratio 3.30, Table 4).
Finally, we sought to determine if any other inflammatory
changes (in addition to those associated with elevated CRP)
were prognostic. Elevated levels of IL-8 and PDGF-AB/BB
were associated with a worse overall survival by univariate
analysis (Table 3). After adjusting for multiple hypothesis
testing, only CRP and PDGR-AB/BB were significant. In
contrast, elevated levels of eotaxin and IP-10 were associ-
ated with lower rates of recurrence (Table 4). However,
after adjusting for multiple hypothesis testing, only CRP
was significantly associated with recurrence.
Discussion
As therapeutic options become more numerous, it becomes
increasingly important to develop tools to select the appro-
priate treatment regimen. In the case of resectable liver
metastases, clinical risk scores (employing factors such as
CEA, size and number of metastases, disease-free interval,
nodal status, margins) effectively stratify most patients by
risk of recurrence and survival [5-13]. When encountering
a patient with a high-risk score, it may prompt the clinician
to defer surgery and/or administer systemic therapy. Simi-
larly, the mGPS has been described to effectively prognosti-
cate for CRC and for CR liver metastases [16-21]. Indeed,
AB
Figure 1 Kaplan-Meier curves depicting survival as a function
of CRP levels. A. Overall survival as a function of serum CRP levels.
B. Disease-free survival as a function of serum CRP levels. Groups
with elevated and normal CRP levels were compared by log
rank test.
Table 4 Inflammatory mediators significantly predictive
of median disease-free survival
Cytokines Hazard ratio 95% CI P-value
CRP 3.30 1.56–7.00 0.002
Eotaxin 0.28 0.11–0.79 0.014
IP-10 0.41 0.17–0.96 0.041
CRP - C-Reactive Protein.
IP - Interferon inducible-protein.
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free and overall survival. mGPS is relatively simple to apply
and presumably reflects underlying tumor and/or host
biology, although it is not entirely clear how this will
affect clinical management.
mGPS is thought to reflect the inflammatory response
secondary to malignancy, although the inflammatory re-
sponse has not been confirmed or characterized. Others
have described changes in circulating inflammatory medi-
ators associated with CRC, including elevated IL-2, IL-6,Table 3 Inflammatory mediators significantly predictive
of median overall survival
Cytokine Hazard ratio 95% CI P-value
CRP 4.00 1.70–9.31 0.001
IL-8 4.96 1.35–17.6 0.014
PDGF-AB/BB 3.16 1.42–6.90 0.005
CRP - C-Reactive Protein.
PDGF - Platelet Derived Growth Factor.and IL-8 without evaluating whether these relate to mGPS
[32-34]. More recently, McMillan’s group has linked
mGPS with IL-6 and tumor necrosis in patients with pri-
mary resected colorectal cancer [35]. The current study
extends on that work in that a more comprehensive panel
of inflammatory mediators was assessed as a function of
mGPS. We have demonstrated that elevated CRP is asso-
ciated with increases in IL-1β, IL-6, IL-12 and IL-15 by
univariate analysis. All of these cytokines with the excep-
tion of IL-6 remained significantly associated with high
CRP levels on multivariate analysis. In general, this con-
firms that a high mGPS is reflective of a proinflammatory
state, with features of a Th1 response.
In addition, a number of other inflammatory mediators
(elevated IL-8 and PDGF-AB/BB, as well as depressed
eotaxin and IP-10) were found to be independently associ-
ated with increased recurrence or truncated survival. IL-8
is a proinflammatory chemokine but is also overexpressed
on metastatic colon cancer cells [36], as well as other can-
cer cells [37]. In the context of cancer, IL-8 is proangio-
genic, attracts neutrophils to tumor, and has a number of
other functions that encourage tumor growth and metas-
tasis. It may also confer chemoresistance [37]. Colon can-
cer is associated with elevated platelet concentrations of
PDGF [38], presumably reflecting a proangiogenic state. Its
expression has not been previously reported to discriminate
biologically meaningful subsets. Eotaxin, a chemokine that
recruits eosinophils, has been reported to be expressed at
higher levels in CRC compared to normal tissue [39,40],
although circulating eotaxin is decreased in CRC patients
compared to disease-free controls and progressively de-
creases with more advanced disease [40]. IP-10 is a chemo-
kine that plays a role in the chemoattraction of monocytes,
endothelial cells and fibroblasts; it is also an inhibitor of
angiogenesis. It is inversely correlated with growth and me-
tastasis in experimental models [41,42]. One previous study
has shown that low circulating levels of IP-10 correlate with
poor prognosis in CRC [43].
In our analysis of cytokines related to prognosis, we did
not formally take into account the effect of clinicopatholog-
ical factors because we could not detect any relationship
between CRP levels and because of the limited sample size.
One potential confounding factor in our series is the
administration of chemotherapy; approximately half of
patients had neoadjuvant chemotherapy. Interestingly,
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and did not receive chemotherapy. In fact, none of the clin-
ical or pathological factors (known to influence prognosis)
that we examined had a significant association with ele-
vated CRP. Therefore, it is unlikely that such confounding
factors influenced our survival analysis. However, in future
studies, it will be important to validate the refined
prognostic cytokine profile in a larger group of patients
undergoing resection of colorectal liver metastases. In
addition, the independent contribution of this panel of
biomarkers on outcomes will have to be evaluated with
a multivariable survival analysis.
In addition to mGPS, a number of other indices of in-
flammation have been described, including neutrophil/
lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR),
and prognostic nutritional index (PNI; a combination of
albumin and lymphocyte count). It is presently unclear
whether all of these indices represent the same type of
inflammatory response (characterized by the same pat-
tern of circulating cytokines). Moreover, it is not known
what indices best reflect the inflammatory state associ-
ated with a poor prognosis. This may well vary between
types of malignancies. In a group of pancreatic cancers
with various stages of disease and undergoing diverse
treatments, NLR was prognostic and other indices were
not [44]. In hepatocellular carcinoma, mGPS performed
better as a prognosticating tool than NLR and PNI [45].
This discrepancy may be related to differences in the na-
ture of the inflammatory response associated with differ-
ent malignancies. Therefore, further study is required to
understand the molecular and disease-related causes of
cancer-associated inflammation, including how that in-
flammatory state may differ between cancers.
An important question related to any studies focusing
on prognostic factors for cancer is whether any factor
that effectively categorizes individuals could be used for
treatment stratification. For example, for primary colon
cancer, adjuvant chemotherapy is recommended for
stage III, and only high risk patients in stage II are typ-
ically considered for adjuvant therapy [46]. Similarly,
many clinicians would advocate administration of neoad-
juvant chemotherapy for high risk patients with colorectal
liver metastases as a means to better select surgical candi-
dates [47]. While higher risk patients have a greater likeli-
hood of benefiting from systemic therapy, in our view,
treatment stratification based on prognostic biomarkers is
not the ultimate goal. Rather, efforts must be directed at
understanding the underlying biology that leads to poor
oncologic outcomes so that novel therapeutic targets can
be identified.
While the cohort studied was small, our data confirm
that mGPS is a reflection of the inflammatory state.
Specifically, elevated CRP indicates a proinflammatory
state with features of a Th1 response. We have alsodemonstrated that prognosis of resected CR liver metasta-
ses is affected by a number of additional inflammatory
(and perhaps angiogenic) events. This study paves the way
to more detailed (and targeted) interrogations on the role
of inflammation in the biology of CRC. In particular, it will
be important to understand the contributions of the
molecular features of tumor that incite a proinflammatory
response, as well as characteristics of the host which
perhaps lead to susceptibility to inflammation. The host
response associated with elevated CRP (including the
metabolic response and effects on distant organs) must
be better understood, to gain an understanding of why
the proinflammatory state is so detrimental. These more
advanced studies will not only add to our capability to
prognosticate; understanding the molecular pathways
that portend a poor prognosis may lead to development
of novel therapeutic strategies.
In all, our studies adhere to the REMARK reporting
guidelines for prognostic tumor markers [48].Conclusions
In patients with colorectal liver metastases, elevated CRP
is associated with increased circulating proinflammatory
cytokines with features of a Th1 response. Elevated
CRP is associated with a shorter disease-free and overall
survival following resection. Other cytokines that influ-
enced survival outcomes included IL-8, PDGF-AB/BB,
eotaxin and IP-10.Additional file
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